Table 1.
Characteristics of Cohorts
| Characteristic/Factor | Cohort A, No. (Col %) | Cohort B, No. (Col %) | Cohort B2, No. (Col %) | Cohort C, No. (Col %) |
|---|---|---|---|---|
| All | 4631 | 2501 | 1674 | 607 |
| Age, y | ||||
| 18–24 | 307 (6.6) | 149 (6.0) | 105 (6.3) | 60 (9.9) |
| 25–34 | 951 (20.5) | 465 (18.6) | 325 (19.4) | 149 (24.5) |
| 35–44 | 1013 (21.9) | 566 (22.6) | 394 (23.5) | 139 (22.9) |
| 45–54 | 1575 (34.0) | 873 (34.9) | 587 (35.1) | 197 (32.5) |
| 55–64 | 785 (17.0) | 448 (17.9) | 263 (15.7) | 62 (10.2) |
| Race/ethnicity | ||||
| American Indian/Alaska Native/Native Hawaiian | 33 (0.7) | 19 (0.8) | 14 (0.8) | 5 (0.8) |
| Asian | 79 (1.7) | 41 (1.6) | 33 (2.0) | 7 (1.2) |
| Black/African American | 2968 (64.1) | 1595 (63.8) | 1075 (64.2) | 429 (70.7) |
| Hispanic/Latino | 318 (6.9) | 197 (7.9) | 133 (7.9) | 34 (5.6) |
| White | 1223 (26.6) | 649 (25.9) | 419 (25.0) | 132 (21.7) |
| Gender | ||||
| Female | 1220 (26.3) | 716 (28.6) | 498 (29.7) | 169 (27.8) |
| Transgender | 48 (1.0) | 18 (0.7) | 12 (0.7) | 5 (0.8) |
| Male | 3363 (72.6) | 1767 (70.7) | 1164 (69.5) | 433 (71.3) |
| HIV/AIDS diagnosis | ||||
| AIDS diagnosis | 1570 (33.9) | 923 (36.9) | 581 (34.7) | 219 (36.1) |
| HIV diagnosis | 3061 (66.1) | 1578 (63.1) | 1093 (65.3) | 388 (63.9) |
| 2014 ADAP program | ||||
| ADAP-funded QHP | 2330 (50.3) | 1306 (52.2) | 1674 (100) | 267 (44.0) |
| Direct ADAP | 2301 (49.7) | 1195 (47.8) | 0 (0) | 340 (56.0) |
| Financial status | ||||
| 251%–400% FPL (tax credit) | 349 (7.5) | 221 (8.8) | 119 (7.1) | 45 (7.4) |
| 139%–250% FPL (tax credit) | 1034 (22.3) | 590 (23.6) | 335 (20.0) | 125 (20.6) |
| 101%–138% FPL (Medicaid gap with tax credit) | 571 (12.3) | 300 (12.0) | 225 (13.4) | 51 (8.4) |
| <100% FPL (Medicaid gap, no tax credit) | 2677 (57.8) | 1390 (55.6) | 995 (59.4) | 386 (63.6) |
| Region of residence | ||||
| Northwest | 473 (10.2) | 322 (12.9) | 530 (31.7) | 42 (6.9) |
| Eastern | 1562 (33.7) | 481 (19.2) | 317 (18.9) | 244 (40.2) |
| Central | 1074 (23.2) | 667 (26.7) | 437 (26.1) | 133 (21.9) |
| Southwest | 511 (11.0) | 324 (13.0) | 177 (10.6) | 72 (11.9) |
| Northern | 1011 (21.8) | 707 (28.3) | 530 (31.7) | 116 (19.1) |
| Average CD4 count, cells/mm3 | 579 ± 3211 | 579 ± 3213 | 592 ± 3135 | 437 ± 3317 |
| Average time since HIV diagnosis, y | 10.3 ± 7.12 | 10.5 ± 7.14 | 10.1 ± 6.96 | 9.4 ± 7.18 |
Cohort A included all people living with HIV (PLWH) who were 18 to 64 years old on January 1, 2014, were AIDS Drug Assistance Program (ADAP) clients by July 1, 2014, did not have Medicare, and had a Social Security Number. Cohort B included members of Cohort A who demonstrated consistent engagement in care in 2014 and 2015, as defined by at least 1 HIV viral load recorded in 2014 and at least 1 HIV viral load between July 1, 2015, and December 31, 2015. Cohort B2 included members of Cohort B with 2015 ADAP-funded Qualified Health Plan (QHP) coverage. Cohort C included members of Cohort B who had an initially detectable viral load in 2014, indicating suboptimally controlled HIV disease.
(1) Data available for 4363 subjects in Cohort A. (2) Data available for 4064 subjects in Cohort A. (3) Data available for 2469 subjects in Cohort B. (4) Data available for 2312 subjects in Cohort B. (5) Data available for 1671 subjects in Cohort B2. (6) Data available for 1537 subjects in Cohort B2. (7) Data available for 605 subjects in Cohort C. (8) Data available for 561 subjects in Cohort C.
Abbreviations: ADAP, AIDS Drug Assistance Program; FPL, Federal Poverty Level; QHP, Qualified Health Plan.